Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus

References

• Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341 8: 556–562.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Bacon BR. Chronic hepatitis C: An age wave of disease burden. Am J Manag Care. 2005; 11 Suppl. 10: S286–S295 quiz S307-S311.
   Google Scholar
• Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect. 2005; 11 2: 86–94.
   Google Scholar
• Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P. A comparison of peginterferon alpha-2a and alpha-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials. Clin Ther. 2010; 32 9: 1565–1577.
   Google Scholar
• Teoh NC, Farrell GC, Chan HL. Individualisation of antiviral therapy for chronic hepatitis C. J Gastroenterol Hepatol. 2010; 25 7: 1206–1216.
   Google Scholar
• Zeuzem S, Poordad F. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: Individualization of treatment duration according to on-treatment virologic response. Curr Med Res Opin. 2010; 26 7: 1733–1743.
   PubMed Web of Science ®Google Scholar
• Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 1997; 26 5: 961–966.
   Google Scholar
• Bodenheimer HCJr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology. 1997; 26 2: 473–477.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA. 2000; 284 4: 450–456.
   PubMed Web of Science ®Google Scholar
• Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol. 2011; 46 4: 545–555.
   Google Scholar
• Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat. 2010703602–703609.
   Google Scholar
• Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF, Wakeland EK, Olsen NJ. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011; 13 2: R38.
   Google Scholar
• Duma D, Collins JB, Chou JW, Cidlowski JA. Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal. 2010; 3 143: ra74.
   PubMed Web of Science ®Google Scholar
• McCaughan GW. Asian perspectives on viral hepatitis: Hepatitis C virus infection. J Gastroenterol Hepatol. 2000; 15 Suppl: G90–G93.
   Google Scholar
• Iturrino J, Sanchez CJ, Ortiz A, Romero CJ, Velazquez V, Costas P, Torres EA. Outcomes of an underserved Hispanic population with chronic hepatitis C treated with pegylated-interferon and ribavirin in a government-sponsored clinic. P R Health Sci J. 2011; 30 1: 9–13.
   Google Scholar
• Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, Albrecht JK, Sulkowski MS, McCone J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat. 2011; 18 4: e134–e143.
   Google Scholar
• Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol. 2010; 44 2: 140–145.
   Google Scholar
• Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Carithers RLJr, Katze MG. Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. Hepatology. 2003; 38 6: 1458–1467.
   Google Scholar
• De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, Buonaguro L, Marincola FM, Wang E, Buonaguro FM. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med. 2009; 7:85–95.
   PubMed Web of Science ®Google Scholar
• Folkers ME, Delker DA, Maxwell CI, Nelson CA, Schwartz JJ, Nix DA, Hagedorn CH. ENCODE tiling array analysis identifies differentially expressed annotated and novel 5′ capped RNAs in hepatitis C infected liver. PLoS One. 2011; 6 2: e14697.
   Google Scholar
• Muffak-Granero K, Bueno P, Olmedo C, Comino AM, Hassan L, Garcia-Alcalde F, Serradilla M, Garcia-Navarro A, Mansilla A, Villar JM, Garrote D, Blanco A, Ferron JA. Study of gene expression profile in liver transplant recipients with hepatitis C virus. Transplant Proc. 2008; 40 9: 2971–2974.
   Google Scholar
• Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H, Mori M. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 2006; 13:947–954.
   Google Scholar
• Shao RX, Hoshida Y, Otsuka M, Kato N, Tateishi R, Teratani T, Shiina S, Taniguchi H, Moriyama M, Kawabe T, Omata M. Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol. 2005; 11 13: 1995–1999.
   PubMed Web of Science ®Google Scholar
• Woodhouse SD, Narayan R, Latham S, Lee S, Antrobus R, Gangadharan B, Luo S, Schroth GP, Klenerman P, Zitzmann N. Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology. 2010; 52 2: 443–453.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162 1: 156–159.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article 3.
   Google Scholar
• Salamov AA, Solovyev VV. Ab initio gene finding in Drosophila genomic DNA. Genome Res. 2000; 10 4: 516–522.
   PubMed Web of Science ®Google Scholar
• Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. 2003; 63 19: 6387–6394.
   Web of Science ®Google Scholar
• Willis S, Hutchins AM, Hammet F, Ciciulla J, Soo WK, White D, van der Spek P, Henderson MA, Gish K, Venter DJ, Armes JE. Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. Genes Chromosomes Cancer. 2003; 36 4: 382–392.
   Google Scholar
• Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. The transcriptional program following p53 activation. Cold Spring Harb Symp Quant Biol. 2000; 65:475–482.
   Google Scholar
• Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med. 2008; 6:66–74.
   Google Scholar
• Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One. 2010; 5 12: e15200.
   PubMedGoogle Scholar
• Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472:481–485.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010; 31 6: 212–219.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhong G, Zhu L, Liu X, Shan Y, Feng H, Bu Z, Chen H, Wang C. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J Immunol. 2010; 184 10: 5777–5790.
   Google Scholar
• Hochrainer K, Mayer H, Baranyi U, Binder B, Lipp J, Kroismayr R. The human HERC family of ubiquitin ligases: Novel members, genomic organization, expression profiling, and evolutionary aspects. Genomics. 2005; 85 2: 153–164.
   Google Scholar
• Hochrainer K, Kroismayr R, Baranyi U, Binder BR, Lipp J. Highly homologous HERC proteins localize to endosomes and exhibit specific interactions with hPLIC and Nm23B. Cell Mol Life Sci. 2008; 65 13: 2105–2117.
   PubMedGoogle Scholar
• Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: Double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology. 1995; 210 2: 508–511.
   Google Scholar
• Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B, Certa U, Foser S. Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res. 2007; 27 8: 675–680.
   Google Scholar
• Hartig SM, He B, Long W, Buehrer BM, Mancini MA. Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. J Cell Biol. 2011; 192 1: 55–67.
   Google Scholar
• Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, Inoue J, Kakazu E, Iwasaki T, Kawagishi N, Shimosegawa T, Sugamura K. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 2010; 101 10: 2145–2155.
   Google Scholar
• Choudhury M, Qadri I, Rahman SM, Schroeder-Gloeckler J, Janssen RC, Friedman JE. C/EBPbeta is AMP kinase sensitive and up-regulates PEPCK in response to ER stress in hepatoma cells. Mol Cell Endocrinol. 2011; 331 1: 102–108.
   Google Scholar
• Artero JM, Herrera EA, Valero PL, Martin Luengo F. Comparative study of 2 rapid techniques (DNA hybridization and chromatography) for the identification of Mycobacterium tuberculosis complex isolated from clinical specimens. Enferm Infecc Microbiol Clin. 1990; 8 8: 505–507.
   Google Scholar
• Liebermann DA, Hoffman B. Gadd45 in stress signaling. J Mol Signal. 2008; 3:15–23.
   PubMedGoogle Scholar
• Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010; 40 2: 294–309.
   PubMed Web of Science ®Google Scholar
• Keyse SM, Emslie EA. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature. 1992; 359 6396: 644–647.
   Google Scholar
• Behari J. The Wnt/beta-catenin signaling pathway in liver biology and disease. Expert Rev Gastroenterol Hepatol. 2010; 4 6: 745–756.
   PubMed Web of Science ®Google Scholar
• Melen K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem. 1996; 271 38: 23478–23486.
   Google Scholar
• Breslow DK, Collins SR, Bodenmiller B, Aebersold R, Simons K, Shevchenko A, Ejsing CS, Weissman JS. Orm family proteins mediate sphingolipid homeostasis. Nature. 2010; 463 7284: 1048–1053.
   PubMed Web of Science ®Google Scholar
• Moreno-Otero R. Therapeutic modalities in hepatitis C: Challenges and development. J Viral Hepat. 2005; 12 1: 10–19.
   Google Scholar
• Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Chayama K. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011; 54:1094–1101.
   PubMed Web of Science ®Google Scholar
• Rallon NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS. 2011; 25:1025–1033.
   PubMedGoogle Scholar
• Lin E, Hwang Y, Chen EY. Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics. 2007; 8 10: 1327–1335.
   Google Scholar
• Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010; 285 50: 38923–38932.
   PubMed Web of Science ®Google Scholar
• Wang H, VerHalen J, Madariaga ML, Xiang S, Wang S, Lan P, Oldenborg PA, Sykes M, Yang YG. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood. 2007; 109 2: 836–842.
   Google Scholar
• Yoon SM, Gerasimidou D, Kuwahara R, Hytiroglou P, Yoo JE, Park YN, Theise ND. Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Hepatology. 2011; 53 3: 964–973.
   PubMed Web of Science ®Google Scholar
• Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J Biol Chem. 2008; 283 3: 1563–1571.
   PubMedGoogle Scholar
• Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006; 7 12: 243–252.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity. Eur J Immunol. 2009; 39 8: 2076–2082.
   Google Scholar
• Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, Tobler LH, Rehermann B, Busch MP, Edlin BR, Talal AH. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol. 2011 In press.
   Google Scholar
• Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011; 121 1: 308–317.
   PubMed Web of Science ®Google Scholar
• Guerrero-Preston R, Siegel A, Renz J, Vlahov D, Neugut A. HCV infection and cryptogenic cirrhosis are risk factors for hepatocellular carcinoma among Latinos in New York City. J Commun Health. 2009; 34 6: 500–505.
   Google Scholar
• Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: A role in the prevention and treatment. J Transl Med. 2010; 8:109–115.
   Google Scholar
• Zhang Z, Bryan JL, DeLassus E, Chang LW, Liao W, Sandell LJ. CCAAT/Enhancer-binding protein β and NF-κB mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1β. J Biol Chem. 2010; 285 43: 33092–33103.
   PubMed Web of Science ®Google Scholar
• Mosbruger TL, Duggal P, Goedert JJ, Kirk GD, Hoots WK, Tobler LH, Busch M, Peters MG, Rosen HR, Thomas DL, Thio CL. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis. 2010; 201 9: 1371–1380.
   Google Scholar
• Tommerup N, Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics. 1995; 27 2: 259–264.
   Google Scholar
• Chen YC, Zhang XW, Niu XH, Xin DQ, Zhao WP, Na YQ, Mao ZB. Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer. Oncogene. 2010; 29 21: 3067–3078.
   Google Scholar